The U.S. stock market's six-day rally runs out of steam amid some disappointing earnings news and a surprisingly weak report on housing sales.
Volatile trading on Wall Street is ramping up the heated debate between the bulls and bears -- and investors increasingly are caught in the middle.
The Nasdaq had its worst day since 2011 as investors dumped biotechnology shares and other industries that have soared during the past year.
The stocks we used to call high-fliers spent most of Friday getting shot down. Tech and biotech led the decline, pushing the Nasdaq to one of its worst days in two years.
Biotech and health care stocks looked like they needed a transfusion of market confidence Monday, as for the second session in a row, their performance was anemic.
Biotechs were in the Wall Street spotlight on Friday, and not in a good way. The sector has had some stellar performers recently, but some analysts now say they’re...
The exclusive club of ultra wealthy individuals -- those with assets of more than $30 million -- increased by about 5,000 last year.
Stocks edge lower in a session dominated by retailers as investors remained cautious ahead of Friday's big monthly jobs report.
Monsanto reports better-than-expected first quarter earnings on higher sales of the company's insect-repelling and herbicide-resistant soybean seeds in Latin America.
Many people don't realize they've been consuming foods with GMO ingredients for years. And if you want to cut back, it'll take some real modifications to your shopping habits.
Stocks are set to rally this morning on hopes for an extension of the debt ceiling deadline, and the owner of Red Lobster faces an investor challenge.
A broad-based selloff on Wall Street followed another bout of heavy selling overseas in trading Wednesday.
A split decision on Wall Street, and a big sell-off for biotech stocks. Some of the biggest Nasdaq stocks, and best performers this year, gave back some of their recent gains.
Last week, the Supreme Court ruled that Monsanto can control how farmers use its genetically-modified soybean seeds. Here's why those little beans are a big deal to you.
Last year was the second most extreme weather year in U.S. history, and the corporate world is at last starting to realize that climate change could cost it a fortune.
A secluded sector of biotechnology -- DNA sequencing and genetic analysis -- is hot once again on Wall Street. Leaders in the sector, like Ilumina, Life Technologies, and...
FDA Panel on Accelerated Approval Process: Pharmaceuticals Fail to Follow-Up
Sanofi-Aventis announced its cancer drug candidate iniparib failed in a late-stage clinical trial. Other pharmaceutical companies have also experienced recent setbacks as...
Biotechnology company Genzyme is holding an analyst and investor meeting Monday focused on the commercial potential of its multiple sclerosis drug Campath as it tries to...
Paris-based pharma Sanofi-Aventis has pushed back its offer deadline for Massachusetts-based biotech Genzyme by six weeks. All other terms, including the $69 per share bid,...